Peringatan Keamanan

Patients experiencing an overdose of carbamoylcholine may experience nausea, sweating, hypotension, hypersalivation, bronchorrhea, miosis, and dyspnea.A226315 Patients should be treated with symptomatic and supportive treatment. Treatment may include atropine, furosemide, epinephrine, and/or dopamine.A226315 Some patients may require intubation.A226315

The oral LD50 in mice is 15 mg/kgL30250 and in rats is 40 mg/kg.L30255

Carbamoylcholine

DB00411

small molecule approved

Deskripsi

Carbamoylcholine, also known as carbachol, is a muscarinic agonist discovered in 1932.A226315 Carbamoylcholine was initially used as a treatment for migraines,A226365 induction of diuresis,A226370 and other parasympathetic effects.

Carbamoylcholine was granted FDA approval on 28 September 1972.L30245

Struktur Molekul 2D

Berat 147.1955
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Data regarding the half life of carbamoylcholine is not readily available.[L30245]
Volume Distribusi Data regarding the volume of distribution of carbamoylcholine is not readily available.[A226315,L30245]
Klirens (Clearance) Data regarding the clearance of carbamoylcholine is not readily available.[L30245]

Absorpsi

Choline esters in general are hydrophilic and therefore poorly absorbed through the gastrointestinal tract and are unlikely to cross the blood brain barrier.A226355,T825 Data regarding the absorption of carbamoylcholine are not readily available.L30245

Metabolisme

The metabolism of carbamoylcholine has not been well described in the literature. It is metabolized to a small extent by acetylcholinesterase.A226310

Rute Eliminasi

Data regarding the route of elimination of carbamoylcholine is not readily available.L30245

Interaksi Obat

121 Data
Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Carbamoylcholine.
Betaxolol The risk or severity of adverse effects can be increased when Betaxolol is combined with Carbamoylcholine.
Metoprolol The risk or severity of adverse effects can be increased when Metoprolol is combined with Carbamoylcholine.
Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with Carbamoylcholine.
Timolol The risk or severity of adverse effects can be increased when Timolol is combined with Carbamoylcholine.
Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Carbamoylcholine.
Propranolol The risk or severity of adverse effects can be increased when Propranolol is combined with Carbamoylcholine.
Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Carbamoylcholine.
Bisoprolol The risk or severity of adverse effects can be increased when Bisoprolol is combined with Carbamoylcholine.
Alprenolol The risk or severity of adverse effects can be increased when Alprenolol is combined with Carbamoylcholine.
Pindolol The risk or severity of adverse effects can be increased when Pindolol is combined with Carbamoylcholine.
Carvedilol The risk or severity of adverse effects can be increased when Carvedilol is combined with Carbamoylcholine.
Propafenone The risk or severity of adverse effects can be increased when Propafenone is combined with Carbamoylcholine.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Carbamoylcholine.
Nadolol The risk or severity of adverse effects can be increased when Nadolol is combined with Carbamoylcholine.
Bevantolol The risk or severity of adverse effects can be increased when Bevantolol is combined with Carbamoylcholine.
Practolol The risk or severity of adverse effects can be increased when Practolol is combined with Carbamoylcholine.
Penbutolol The risk or severity of adverse effects can be increased when Penbutolol is combined with Carbamoylcholine.
Oxprenolol The risk or severity of adverse effects can be increased when Oxprenolol is combined with Carbamoylcholine.
Dexpropranolol The risk or severity of adverse effects can be increased when Dexpropranolol is combined with Carbamoylcholine.
Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Carbamoylcholine.
Nebivolol The risk or severity of adverse effects can be increased when Nebivolol is combined with Carbamoylcholine.
Bufuralol The risk or severity of adverse effects can be increased when Bufuralol is combined with Carbamoylcholine.
Bopindolol The risk or severity of adverse effects can be increased when Bopindolol is combined with Carbamoylcholine.
Bupranolol The risk or severity of adverse effects can be increased when Bupranolol is combined with Carbamoylcholine.
Indenolol The risk or severity of adverse effects can be increased when Indenolol is combined with Carbamoylcholine.
Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Carbamoylcholine.
Levobetaxolol The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Carbamoylcholine.
Talinolol The risk or severity of adverse effects can be increased when Talinolol is combined with Carbamoylcholine.
Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Carbamoylcholine.
Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with Carbamoylcholine.
Esatenolol The risk or severity of adverse effects can be increased when Esatenolol is combined with Carbamoylcholine.
Cloranolol The risk or severity of adverse effects can be increased when Cloranolol is combined with Carbamoylcholine.
Mepindolol The risk or severity of adverse effects can be increased when Mepindolol is combined with Carbamoylcholine.
Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with Carbamoylcholine.
Tertatolol The risk or severity of adverse effects can be increased when Tertatolol is combined with Carbamoylcholine.
Landiolol The risk or severity of adverse effects can be increased when Landiolol is combined with Carbamoylcholine.
Cimetropium Carbamoylcholine may decrease the anticholinergic activities of Cimetropium.
Pegvisomant The risk or severity of adverse effects can be increased when Pegvisomant is combined with Carbamoylcholine.
Mefloquine The risk or severity of adverse effects can be increased when Mefloquine is combined with Carbamoylcholine.
Tacrine The risk or severity of adverse effects can be increased when Tacrine is combined with Carbamoylcholine.
Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Carbamoylcholine.
Profenamine The risk or severity of adverse effects can be increased when Profenamine is combined with Carbamoylcholine.
Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carbamoylcholine.
Gallamine triethiodide The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Carbamoylcholine.
Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Carbamoylcholine.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Carbamoylcholine.
Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Carbamoylcholine.
Pyridostigmine The risk or severity of adverse effects can be increased when Pyridostigmine is combined with Carbamoylcholine.
Nizatidine The risk or severity of adverse effects can be increased when Nizatidine is combined with Carbamoylcholine.
Galantamine The risk or severity of adverse effects can be increased when Galantamine is combined with Carbamoylcholine.
Isoflurophate The risk or severity of adverse effects can be increased when Isoflurophate is combined with Carbamoylcholine.
Diethylcarbamazine The risk or severity of adverse effects can be increased when Diethylcarbamazine is combined with Carbamoylcholine.
Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Carbamoylcholine.
Minaprine The risk or severity of adverse effects can be increased when Minaprine is combined with Carbamoylcholine.
Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Carbamoylcholine.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Carbamoylcholine.
Hexafluronium The risk or severity of adverse effects can be increased when Hexafluronium is combined with Carbamoylcholine.
Demecarium The risk or severity of adverse effects can be increased when Demecarium is combined with Carbamoylcholine.
Physostigmine The risk or severity of adverse effects can be increased when Physostigmine is combined with Carbamoylcholine.
Rivastigmine The risk or severity of adverse effects can be increased when Rivastigmine is combined with Carbamoylcholine.
Edrophonium The risk or severity of adverse effects can be increased when Edrophonium is combined with Carbamoylcholine.
Procainamide The risk or severity of adverse effects can be increased when Procainamide is combined with Carbamoylcholine.
Memantine The risk or severity of adverse effects can be increased when Memantine is combined with Carbamoylcholine.
Ambenonium The risk or severity of adverse effects can be increased when Ambenonium is combined with Carbamoylcholine.
Tubocurarine The risk or severity of adverse effects can be increased when Tubocurarine is combined with Carbamoylcholine.
Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Carbamoylcholine.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Carbamoylcholine.
Decamethonium The risk or severity of adverse effects can be increased when Decamethonium is combined with Carbamoylcholine.
Pancuronium The risk or severity of adverse effects can be increased when Pancuronium is combined with Carbamoylcholine.
Pipecuronium The risk or severity of adverse effects can be increased when Pipecuronium is combined with Carbamoylcholine.
Ginkgo biloba The risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Carbamoylcholine.
Neostigmine The risk or severity of adverse effects can be increased when Neostigmine is combined with Carbamoylcholine.
Bambuterol The risk or severity of adverse effects can be increased when Bambuterol is combined with Carbamoylcholine.
1,10-Phenanthroline The risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Carbamoylcholine.
Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Carbamoylcholine.
Huperzine A The risk or severity of adverse effects can be increased when Huperzine A is combined with Carbamoylcholine.
Phenserine The risk or severity of adverse effects can be increased when Phenserine is combined with Carbamoylcholine.
Regramostim The risk or severity of adverse effects can be increased when Regramostim is combined with Carbamoylcholine.
Aprotinin The risk or severity of adverse effects can be increased when Aprotinin is combined with Carbamoylcholine.
Betaine The risk or severity of adverse effects can be increased when Betaine is combined with Carbamoylcholine.
Capsaicin The risk or severity of adverse effects can be increased when Capsaicin is combined with Carbamoylcholine.
Coumaphos The risk or severity of adverse effects can be increased when Coumaphos is combined with Carbamoylcholine.
Dichlorvos The risk or severity of adverse effects can be increased when Dichlorvos is combined with Carbamoylcholine.
Fenthion The risk or severity of adverse effects can be increased when Fenthion is combined with Carbamoylcholine.
Metrifonate The risk or severity of adverse effects can be increased when Metrifonate is combined with Carbamoylcholine.
Acotiamide The risk or severity of adverse effects can be increased when Acotiamide is combined with Carbamoylcholine.
Methanesulfonyl Fluoride The risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Carbamoylcholine.
Paraoxon The risk or severity of adverse effects can be increased when Paraoxon is combined with Carbamoylcholine.
Tyrothricin The risk or severity of adverse effects can be increased when Tyrothricin is combined with Carbamoylcholine.
Ipidacrine The risk or severity of adverse effects can be increased when Ipidacrine is combined with Carbamoylcholine.
Distigmine The risk or severity of adverse effects can be increased when Distigmine is combined with Carbamoylcholine.
Tretamine The risk or severity of adverse effects can be increased when Tretamine is combined with Carbamoylcholine.
Posiphen The risk or severity of adverse effects can be increased when Posiphen is combined with Carbamoylcholine.
Methylphosphinic Acid The risk or severity of adverse effects can be increased when Methylphosphinic Acid is combined with Carbamoylcholine.
Capreomycin The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Capreomycin.
Framycetin The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Framycetin.
Amikacin The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Amikacin.
Tobramycin The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Tobramycin.
Gentamicin The therapeutic efficacy of Carbamoylcholine can be decreased when used in combination with Gentamicin.

Target Protein

Muscarinic acetylcholine receptor M1 CHRM1
Muscarinic acetylcholine receptor M2 CHRM2
Neuronal acetylcholine receptor subunit alpha-2 CHRNA2
Muscarinic acetylcholine receptor M3 CHRM3
Muscarinic acetylcholine receptor M4 CHRM4

Referensi & Sumber

Synthesis reference: Major, R.T. and Bonnett, H.T.; U.S. Patent 2,374,367; April 24,1945; assigned to Merck & Co., Inc.
Artikel (PubMed)
  • PMID: 19006330
    Rosenberry TL, Sonoda LK, Dekat SE, Cusack B, Johnson JL: Analysis of the reaction of carbachol with acetylcholinesterase using thioflavin T as a coupled fluorescence reporter. Biochemistry. 2008 Dec 9;47(49):13056-63. doi: 10.1021/bi8015197.
  • PMID: 16740173
    Schulz M, Graefe T, Stuby K, Andresen H, Kupfermann N, Schmoldt A: Case report: acute unintentional carbachol intoxication. Crit Care. 2006;10(3):R84. doi: 10.1186/cc4937. Epub 2006 Jun 1.
  • PMID: 30844190
    Pakala RS, Brown KN, Preuss CV: Cholinergic Medications .
  • PMID: 30137840
    Dotiwala AK, McCausland C, Samra NS: Anatomy, Head and Neck, Blood Brain Barrier .
  • PMID: 3230520
    Wood TO: Effect of carbachol on postoperative intraocular pressure. J Cataract Refract Surg. 1988 Nov;14(6):654-6. doi: 10.1016/s0886-3350(88)80034-8.
  • PMID: 20786063
    James AK: Oral Carbachol for Prevention of Migraine. Br Med J. 1945 May 12;1(4401):663-4. doi: 10.1136/bmj.1.4401.663.
  • PMID: 18874896
    FRANCIS RR: The effect of carbachol and of mecholyl on the urinary bladder. J Urol. 1948 Aug;60(2):290-6. doi: 10.1016/s0022-5347(17)69236-x.
Textbook
  • ISBN: 978-0-07-176402-5
    Pappano AJ (2012). Cholinoceptor-Activating & Cholinesterase-Inhibiting Drugs. In Basic & Clinical Pharmacology (12th Edition) (12th ed., pp. 97-113). McGraw Hill.

Contoh Produk & Brand

Produk: 12 • International brands: 2
Produk
  • Carbachol
    Tablet • 2 mg • Oral • Canada • Approved
  • Carbachol Injection Liq Sc 0.25mg/ml
    Liquid • .25 mg / mL • Subcutaneous • Canada • Approved
  • Carbachol Intraocular Solution 0.01%
    Liquid • 0.1 mg / mL • Intraocular • Canada • Approved
  • Carbachol Tab 2mg
    Tablet • 2 mg / tab • Oral • Canada • Approved
  • Carbastat
    Injection, solution • 0.1 mg/1mL • Intraocular • US • Approved
  • Carbastat
    Solution • 0.01 % • Intraocular • Canada • Approved
  • Isopto Carbachol
    Solution • 15 mg/1mL • Ophthalmic • US
  • Isopto Carbachol
    Solution • 30 mg/1mL • Ophthalmic • US
Menampilkan 8 dari 12 produk.
International Brands
  • Carboptic — NutraMax
  • Mioticol — Farmigea

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul